PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial.
PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial.
复制标题
PNPLA3、TM6SF2和MBOAT7对非酒精性脂肪肝营养治疗反应的影响：一项随机对照试验
DOI：
10.3389/fmed.2021.734847
复制
发表时间：
2021
影响因子：
3.9
通讯作者：
Federico A
中科院分区：
文献类型：
--
作者：
Dallio M;Masarone M;Romeo M;Tuccillo C;Morisco F;Persico M;Loguercio C;Federico A
PNPLA 3、TM 6SF 2和MBOAT 7基因在非酒精性脂肪性肝病（NAFLD）的发展和恶化中起着至关重要的作用。然而，关于其治疗反应影响的数据很少。本试验的目的是探索在携带PNPLA 3-rs738409、TM 6SF 2-rs 58542926或MBOAT 7-rs641738遗传变体的NAFLD患者中口服施用水飞蓟宾-磷脂复合物（303 mg水飞蓟宾-磷脂复合物、10 μg维生素D和15 mg维生素E，每天两次，持续6个月）的效果。材料与方法：总之，92名经活检证实的NAFLD患者被分为30名NAFLD野生型对照组、30名野生型治疗患者和32名突变治疗患者。我们评估了基线和治疗结束时的空腹血糖（FPG）、胰岛素血症、HOMA-IR、天冬氨酸和丙氨酸氨基转移酶（AST、ALT）、C反应蛋白（CRP）、硫代巴比妥酸反应物质（TBARS）、僵硬度、控制衰减参数（CAP）、每日饮食摄入量和体力活动。结果如下：野生型治疗组显示出FPG、胰岛素血症、HOMA-IR、ALT、CRP和TBARS的显著改善（p < 0.05），而在其他两个研究组中没有记录到改善。与突变组相比，NAFLD野生型治疗的患者显示出更高的有用治疗结果的可能性（p < 0.01），其从处方治疗方案获得，与年龄、性别、合并症、药物、CAP和僵硬无关。讨论内容：所评估的突变与对基于水飞蓟宾的治疗方案无应答独立相关，并且在这种情况下可以被认为是有用的预测标志物。临床试验注册号：www.ClinicalTrials.gov，标识符：NCT 04640324。
Introduction: PNPLA3, TM6SF2, and MBOAT7 genes play a crucial role in non-alcoholic fatty liver disease (NAFLD) development and worsening. However, few data are available on their treatment response influence. The aim of this trial is to explore the effect derived from silybin-phospholipids complex (303 mg of silybin-phospholipids complex, 10 μg of vitamin D, and 15 mg of vitamin E twice a day for 6 months) oral administration in NAFLD patients carrying PNPLA3-rs738409, TM6SF2-rs58542926, or MBOAT7-rs641738 genetic variants. Materials and Methods: In all, 92 biopsy-proven NAFLD patients were grouped in 30 NAFLD wild type controls, 30 wild type treated patients, and 32 mutated treated ones. We assessed glycemia (FPG), insulinemia, HOMA-IR, aspartate and alanine aminotransferases (AST, ALT), C-reactive protein (CRP), thiobarbituric acid reactive substance (TBARS), stiffness, controlled attenuation parameter (CAP), dietary daily intake, and physical activity at baseline and end of treatment. Results: The wild-type treated group showed a significant improvement of FPG, insulinemia, HOMA-IR, ALT, CRP, and TBARS (p < 0.05), whereas no improvements were recorded in the other two study groups. NAFLD wild type treated patients showed higher possibilities of useful therapeutic outcome (p < 0.01), obtained from the prescribed therapeutic regimen, independently from age, sex, comorbidities, medications, CAP, and stiffness in comparison to the mutated group. Discussion: The assessed mutations are independently associated with no response to a silybin-based therapeutic regimen and could be considered as useful predictive markers in this context. Clinical Trial Registry Number: www.ClinicalTrials.gov, identifier: NCT04640324.
登录
查看更多内容
影响因子：
7.7
作者：
Forouhi NG;Luan J;Cooper A;Boucher BJ;Wareham NJ
通讯作者：
Wareham NJ
影响因子：
4.6
作者：
Lama, Stefania;Vanacore, Daniela;Stiuso, Paola
通讯作者：
Stiuso, Paola
影响因子：
29.4
作者：
Chalasani N;Guo X;Loomba R;Goodarzi MO;Haritunians T;Kwon S;Cui J;Taylor KD;Wilson L;Cummings OW;Chen YD;Rotter JI;Nonalcoholic Steatohepatitis Clinical Research Network
通讯作者：
Nonalcoholic Steatohepatitis Clinical Research Network
影响因子：
7.4
作者：
Loguercio, Carmela;Andreone, Pietro;Federico, Alessandro
通讯作者：
Federico, Alessandro
DOI：
10.1016/j.jpba.2017.02.058
发表时间：
2017-06-05
影响因子：
3.4
作者：
Nicolucci, Carla;Erric, Sonia;Diano, Nadia
通讯作者：
Diano, Nadia